FY2026 Earnings Estimate for RYTM Issued By HC Wainwright

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Analysts at HC Wainwright issued their FY2026 EPS estimates for Rhythm Pharmaceuticals in a research note issued to investors on Monday, March 3rd. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($1.49) for the year. HC Wainwright currently has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.03). The business had revenue of $41.83 million during the quarter, compared to analysts’ expectations of $38.48 million. Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%.

Other research analysts have also recently issued reports about the stock. The Goldman Sachs Group boosted their price objective on shares of Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Oppenheimer began coverage on shares of Rhythm Pharmaceuticals in a research note on Friday, December 20th. They set an “outperform” rating and a $76.00 target price for the company. Needham & Company LLC restated a “buy” rating and issued a $64.00 price target on shares of Rhythm Pharmaceuticals in a research note on Thursday, February 27th. JMP Securities reiterated a “market outperform” rating and set a $75.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Monday, December 23rd. Finally, TD Cowen increased their target price on Rhythm Pharmaceuticals from $55.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $68.27.

Rhythm Pharmaceuticals Stock Performance

NASDAQ RYTM opened at $53.22 on Wednesday. The company has a market capitalization of $3.27 billion, a price-to-earnings ratio of -12.29 and a beta of 2.30. The stock has a 50-day moving average of $56.79 and a 200 day moving average of $54.48. Rhythm Pharmaceuticals has a one year low of $35.17 and a one year high of $68.58.

Insider Buying and Selling at Rhythm Pharmaceuticals

In other news, insider Joseph Shulman sold 1,281 shares of Rhythm Pharmaceuticals stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total transaction of $76,129.83. Following the transaction, the insider now directly owns 2,657 shares of the company’s stock, valued at $157,905.51. The trade was a 32.53 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO David P. Meeker sold 4,278 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $59.43, for a total value of $254,241.54. Following the transaction, the chief executive officer now owns 189,927 shares of the company’s stock, valued at approximately $11,287,361.61. This trade represents a 2.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 32,787 shares of company stock valued at $1,901,443. Company insiders own 5.60% of the company’s stock.

Institutional Trading of Rhythm Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of RYTM. Loomis Sayles & Co. L P bought a new position in Rhythm Pharmaceuticals in the 3rd quarter worth $33,353,000. Janus Henderson Group PLC grew its position in shares of Rhythm Pharmaceuticals by 103.9% during the fourth quarter. Janus Henderson Group PLC now owns 1,219,554 shares of the company’s stock worth $68,309,000 after purchasing an additional 621,432 shares in the last quarter. Marshall Wace LLP raised its stake in Rhythm Pharmaceuticals by 70.4% during the 4th quarter. Marshall Wace LLP now owns 692,803 shares of the company’s stock valued at $38,783,000 after purchasing an additional 286,188 shares during the period. Norges Bank purchased a new position in Rhythm Pharmaceuticals in the 4th quarter worth approximately $11,512,000. Finally, JPMorgan Chase & Co. boosted its stake in Rhythm Pharmaceuticals by 224.3% in the 4th quarter. JPMorgan Chase & Co. now owns 264,585 shares of the company’s stock worth $14,811,000 after purchasing an additional 182,993 shares during the period.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.